Following on from information provided to NICE by the company in October 2022, the appraisal of Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 3930 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 04 October 2023 | Discontinued. Following on from information provided to NICE by the company in October 2022, the appraisal of Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 04 October 2022 | Suspended. As you will be aware the Department for Health & Social Care has asked NICE to carry out an appraisal of Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma ID3930. For information, the company have announced that the trial did not meet its primary endpoint and therefore they will no longer be pursuing a Marketing Authorisation Application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes. |
For further information on our processes and methods, please see our CHTE processes and methods manual